CNS Pharmaceuticals (NASDAQ: CNSP) recently announced rapid enrollment in its potentially pivotal study involving its flagship drug candidate, Berubicin, and is moving closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”). “The Texas-based company has clinical trial sites operating in the U.S., Italy, France, … Continue reading InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment